Industry Survey

The aim of this survey is to gain a better understanding of industry motivations, and the personalities working within this field in order to create a more tailored and customer focused agenda for the EpiCongress London.

This short survey contains 10 questions and I do not anticipate them taking you more than 5 minutes to answer. After that the team at Hanson Wade will do the hard work of collating and analyzing the data to then be able to share the findings with you. Hopefully you should find the process interesting as well.

The Epigenetics Revolution is upon us…

EpiCongress London is a premier networking, interactive and solution-led conference that addresses how to understand the basic mechanisms behind genome regulation and chromatin function. 

This is a meeting where attendees discover industry-defining information, and expand their network to achieve to ensure effective application of epigenetic science to ensure the success of current and future drug candidates.

Epigenetics is a field growing in importance when it comes to understanding a cell’s transformation to cancer so understanding  the epigenetic mechanisms involved will have a significant impact on cancer prevention, diagnosis and therapy. 

EpiCongress London will ensure you develop a cutting edge understanding for making clinically relevant predictions and tap into the potential of epigenetics to generate new cancer drugs:

  • Learn about genome regulation to explore the therapeutic opportunities in altered epigenomic states
  • Explore the biology and pharmacological properties behind selected HMT and demethylases compounds 
  • Get to grips with heterogeneity in neuropsychiatric disorders to see  how it can impact your therapeutic strategies
  • Get an insight into unpublished data from the industry’s exciting EZH2 programs
  • Understand the chemistry behind LSD1 histone methyltransferases and demethylases to develop potent and specific small molecule inhibitors
  • Improve your target validation by identifying which inhibitors are ticking all the boxes for pharma
  • Choose the most effective biomarker strategies for your program and discuss what clinical biomarkers will look like for novel epigenetic drugs
  • Discover how companies are currently selecting their PK/PD endpoints for early clinical trials
  • Learn from those who have achieved successful patient selection so far in phase I & II trials 


2013-Featured Speakers

  • Andrea Cochran Senior Scientist Genentech

  • Bob CopelandExecutive VP & CSO Epizyme

  • Peter Staller Director of Oncology Research EpiTherapeutics

  • Dominique Verhelle Director of Epigenetics Pfizer